Evaluation of the efficacy of XELOX for Japanese patients with completely resected stage II / stage III rectal cancer

Trial Profile

Evaluation of the efficacy of XELOX for Japanese patients with completely resected stage II / stage III rectal cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top